SubHero Banner

Mavyret® (glecaprevir/pibrentasvir) – Label update

September 26, 2019 - The FDA announced the approval of AbbVie’s Mavyret (glecaprevir/pibrentasvir), for an 8-week duration for the treatment of adults and children ages 12 years and older or weighing at least 45 kg who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV.

Download PDF